Cargando…
Repurposed drugs for COVID-19: threshold and proof requirements for trials
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425289/ https://www.ncbi.nlm.nih.gov/pubmed/34508887 http://dx.doi.org/10.1016/j.cmi.2021.08.024 |
| _version_ | 1783749826022735872 |
|---|---|
| author | Paul, Mical Kalil, Andre C. |
| author_facet | Paul, Mical Kalil, Andre C. |
| author_sort | Paul, Mical |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8425289 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84252892021-09-09 Repurposed drugs for COVID-19: threshold and proof requirements for trials Paul, Mical Kalil, Andre C. Clin Microbiol Infect Commentary European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2021-12 2021-09-08 /pmc/articles/PMC8425289/ /pubmed/34508887 http://dx.doi.org/10.1016/j.cmi.2021.08.024 Text en © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Commentary Paul, Mical Kalil, Andre C. Repurposed drugs for COVID-19: threshold and proof requirements for trials |
| title | Repurposed drugs for COVID-19: threshold and proof requirements for trials |
| title_full | Repurposed drugs for COVID-19: threshold and proof requirements for trials |
| title_fullStr | Repurposed drugs for COVID-19: threshold and proof requirements for trials |
| title_full_unstemmed | Repurposed drugs for COVID-19: threshold and proof requirements for trials |
| title_short | Repurposed drugs for COVID-19: threshold and proof requirements for trials |
| title_sort | repurposed drugs for covid-19: threshold and proof requirements for trials |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425289/ https://www.ncbi.nlm.nih.gov/pubmed/34508887 http://dx.doi.org/10.1016/j.cmi.2021.08.024 |
| work_keys_str_mv | AT paulmical repurposeddrugsforcovid19thresholdandproofrequirementsfortrials AT kalilandrec repurposeddrugsforcovid19thresholdandproofrequirementsfortrials |